Incyte [INCY] vs Alnylam [ALNY] Detailed Stock Comparison
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Incyte Corporation wins in 15 metrics, Alnylam Pharmaceuticals Inc. wins in 5 metrics, with 0 ties. Incyte Corporation appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Incyte Corporation | Alnylam Pharmaceuticals Inc. | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 15.01 | 132.73 | Incyte Corporation |
| Price-to-Book Ratio | 3.70 | 52.09 | Incyte Corporation |
| Debt-to-Equity Ratio | 1.06 | 376.19 | Incyte Corporation |
| PEG Ratio | 0.33 | 22.00 | Incyte Corporation |
| EV/EBITDA | 10.85 | 74.03 | Incyte Corporation |
| Profit Margin (TTM) | 25.03% | 8.45% | Incyte Corporation |
| Operating Margin (TTM) | 25.57% | 12.01% | Incyte Corporation |
| EBITDA Margin (TTM) | 25.57% | 12.01% | Incyte Corporation |
| Return on Equity | 29.87% | 73.28% | Alnylam Pharmaceuticals Inc. |
| Return on Assets (TTM) | 13.57% | 6.81% | Incyte Corporation |
| Free Cash Flow (TTM) | $1.33B | $465.38M | Incyte Corporation |
| 1-Year Return | 48.69% | -0.85% | Incyte Corporation |
| Price-to-Sales Ratio (TTM) | 3.72 | 11.16 | Incyte Corporation |
| Enterprise Value | $15.62B | $41.25B | Alnylam Pharmaceuticals Inc. |
| EV/Revenue Ratio | 3.04 | 11.11 | Incyte Corporation |
| Gross Profit Margin (TTM) | 91.96% | 75.60% | Incyte Corporation |
| Revenue per Share (TTM) | $26 | $28 | Alnylam Pharmaceuticals Inc. |
| Earnings per Share (Diluted) | $6.41 | $2.34 | Incyte Corporation |
| Beta (Stock Volatility) | 0.86 | 0.38 | Alnylam Pharmaceuticals Inc. |
| Short % of Float | 8.06% | 5.05% | Alnylam Pharmaceuticals Inc. |
Incyte Corporation vs Alnylam Pharmaceuticals Inc. Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Incyte Corporation | 6.21% | -5.03% | -5.06% | -7.82% | -9.09% | -9.07% |
| Alnylam Pharmaceuticals Inc. | 2.26% | -3.17% | -3.96% | -11.98% | -38.46% | -28.50% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Incyte Corporation | 48.69% | 54.69% | 16.09% | 13.87% | 485.95% | 2,160.28% |
| Alnylam Pharmaceuticals Inc. | -0.85% | 55.93% | 107.40% | 330.17% | 2,975.15% | 1,859.64% |
Performance & Financial Health Analysis: Incyte Corporation vs Alnylam Pharmaceuticals Inc.
| Metric | INCY | ALNY |
|---|---|---|
| Market Information | ||
| Market Cap | $19.00B | $41.87B |
| Market Cap Category | Large cap | Large cap |
| 10 Day Avg. Volume | 1,289,416 | 1,075,369 |
| 90 Day Avg. Volume | 1,525,109 | 1,141,756 |
| Last Close | $97.97 | $292.58 |
| 52 Week Range | $64.72 - $112.29 | $283.10 - $495.55 |
| % from 52W High | -12.75% | -40.96% |
| All-Time High | $153.15 (Mar 13, 2017) | $495.55 (Oct 20, 2025) |
| % from All-Time High | -36.03% | -40.96% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.28% | 0.85% |
| Quarterly Earnings Growth | 0.49% | 0.85% |
| Financial Health | ||
| Profit Margin (TTM) | 0.25% | 0.08% |
| Operating Margin (TTM) | 0.26% | 0.12% |
| Return on Equity (TTM) | 0.30% | 0.73% |
| Debt to Equity (MRQ) | 1.06 | 376.19 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $26.04 | $5.96 |
| Cash per Share (MRQ) | $17.99 | $21.93 |
| Operating Cash Flow (TTM) | $1.41B | $524.08M |
| Levered Free Cash Flow (TTM) | $609.55M | $128.79M |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | N/A |
| Last 12-Month Dividend | N/A | N/A |
Valuation & Enterprise Metrics Analysis: Incyte Corporation vs Alnylam Pharmaceuticals Inc.
| Metric | INCY (Apr 24, 2026) | ALNY (Apr 24, 2026) |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 15.01 | 132.73 |
| Forward P/E | 11.03 | 22.00 |
| PEG Ratio | 0.33 | 22.00 |
| Price to Sales (TTM) | 3.72 | 11.16 |
| Price to Book (MRQ) | 3.70 | 52.09 |
| Market Capitalization | ||
| Market Capitalization | $19.00B | $41.87B |
| Enterprise Value | $15.62B | $41.25B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 3.04 | 11.11 |
| Enterprise to EBITDA | 10.85 | 74.03 |
| Risk & Other Metrics | ||
| Beta | 0.86 | 0.38 |
| Book Value per Share (MRQ) | $26.04 | $5.96 |
Financial Statements Comparison: Incyte Corporation vs Alnylam Pharmaceuticals Inc.
Financial Metrics
Loading Financial Charts...
Revenue
Operating Margin
Profit Margin
Long Term Debt
Income Flow Analysis
Financial Statements Comparison
Income Statement
| Metric | INCY (2025) | ALNY (2025) |
|---|---|---|
| Revenue/Sales | 5.14B | 3.71B |
| Cost of Goods Sold | 372.10M | 681.87M |
| COGS % of Revenue | 7.2% | 18.4% |
| Gross Profit | 4.77B | 3.03B |
| Gross Margin | 92.8% | 81.6% |
| Research & Development | 2.05B | 1.32B |
| Operating Income (EBIT) | 1.34B | 501.58M |
| Operating Margin | 26.1% | 13.5% |
| EBITDA | 1.57B | 676.22M |
| EBITDA Margin | 30.5% | 18.2% |
| Pre-Tax Income | 1.66B | 323.15M |
| Pre-Tax Income % of Revenue | 32.4% | 8.7% |
| Income Tax | 377.80M | 9.41M |
| Income Tax % of Revenue | 7.3% | 0.3% |
| Net Income (Profit) | 1.29B | 313.75M |
| Profit Margin | 25.0% | 8.4% |
Balance Sheet & Liquidity Metrics
| Metric | INCY (2025) | ALNY (2025) |
|---|---|---|
| Cash & Equivalents | 3.10B | 1.66B |
| Total Current Assets | 5.02B | 4.05B |
| Total Current Assets % of Revenue | 97.7% | 109.1% |
| Total Current Liabilities | 1.52B | 1.47B |
| Total Current Liabilities % of Revenue | 29.5% | 39.5% |
| Long-Term Debt | 30.20M | 1.23B |
| Long-Term Debt % of Revenue | 0.6% | 33.2% |
| Total Shareholders Equity | 5.17B | 789.18M |
| Retained Earnings | 213.77M | -6.70B |
| Retained Earnings % of Revenue | 4.2% | -180.5% |
| Property, Plant & Equipment | 305.12M | 384.79M |
Cash Flow Statement Comparison
| Metric | INCY (2025) | ALNY (2025) |
|---|---|---|
| Operating Cash Flow | 1.66B | 639.50M |
| Operating Cash Flow % of Revenue | 32.3% | 17.2% |
| Capital Expenditures | N/A | -58.70M |
| Free Cash Flow | 1.33B | 465.38M |
| FCF Margin | 25.9% | 12.5% |
| Debt Repayment | -4.54M | -1.19B |
| Common Stock Repurchase | 0 | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | INCY | ALNY |
|---|---|---|
| Shares Short | 11.44M | 5.06M |
| Short Ratio | 7.13 | 4.49 |
| Short % of Float | 8.06% | 5.05% |
| Shares Outstanding | 198.46M | 132.38M |
| Float Shares | 166.62M | 132.07M |
| % Held by Insiders | 1.96% | 0.19% |
| % Held by Institutions | 105.52% | 101.05% |
| % Held by Public | -7.48% | -1.24% |
Dividend Analysis & Yield Comparison: Incyte Corporation vs Alnylam Pharmaceuticals Inc.
| Metric | INCY | ALNY |
|---|---|---|
| Last 12-Month Dividend | N/A | N/A |
| Last 12-Month Dividend Yield | N/A | N/A |
| 3-Year Avg Annual Dividend | N/A | N/A |
| 3-Year Avg Dividend Yield | N/A | N/A |
| 3-Year Total Dividends | N/A | N/A |
| Ex-Dividend Date | N/A | N/A |